VEGFA and diffuse large B-cell lymphoma: Apart from the direct effect on immune and tumor cells, surprisingly, the application of the VEGF-A inhibiting antibody bevacizumab to R-CHOP therapy increased adverse cardiac events, yet without increasing the therapeutic efficacy in DLBCL patients (214, 215).